113276-94-1
Chemical Structure
H-8 dihydrochloride
- CAS No.: 113276-94-1
- Formula:C12H17Cl2N3O2S
- Molecular Weight:338.25
IUPAC Name: N-(2-(methylamino)ethyl)isoquinoline-5-sulfonamide dihydrochloride
InChIKey: RJJLZYZEVNCZIW-UHFFFAOYSA-N
SMILES: O=S(C1=CC=CC2=C1C=CN=C2)(NCCNC)=O.Cl.Cl
Biological Activity: H-8 dihydrochloride is a selective Cyclic nucleotide-dependent protein kinase inhibitor. H-8 dihydrochloride potently inhibits cGMP- and cAMP-dependent protein phosphorylation. H-8 dihydrochloride enhances the vasodilatory effect induced by 8-bromo-cAMP (HY-12306A). H-8 dihydrochloride fails to attenuate the vasodilatory effects induced by 8-bromo-cGMP (HY-101379A), atrial natriuretic peptide II, or Sodium nitroprusside (HY-B0564) in rat aorta[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
H-8 dihydrochloride | 99.19% | H-8 dihydrochloride is a selective Cyclic nucleotide-dependent protein kinase inhibitor. H-8 dihydrochloride potently inhibits cGMP- and cAMP-dependent protein phosphorylation. H-8 dihydrochloride enhances the vasodilatory effect induced by 8-bromo-cAMP (HY-12306A). H-8 dihydrochloride fails to attenuate the vasodilatory effects induced by 8-bromo-cGMP (HY-101379A), atrial natriuretic peptide II, or Sodium nitroprusside (HY-B0564) in rat aorta. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. O'Grady SM, et al. Cyclic nucleotide-dependent protein kinase inhibition by H-8: effects on ion transport. Am J Physiol. 1988;254(1 Pt 1):C115-C121. [Content Brief]
- [2]. Daugirdas JT, et al. Effect of H-8, an isoquinolinesulfonamide inhibitor of cyclic nucleotide-dependent protein kinase, on cAMP- and cGMP-mediated vasorelaxation. Blood Vessels. 1991;28(5):366-371. [Content Brief]
- [3]. Niisato N, et al. Effects of PKA inhibitors, H-compounds, on epithelial Na+ channels via PKA-independent mechanisms. Life Sci. 1999;65(10):PL109-PL114. [Content Brief]
